newsfilter
← Latest News
GlobeNewswire·

Ardelyx to Participate at the Jefferies Global Healthcare Conference in London

  • Ardelyx Inc. (Nasdaq: ARDX) will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, at 11:30 a.m. GMT / 6:30 a.m. ET.
  • The live webcast will be accessible via the Events & Presentations page at ir.ardelyx.com, with a replay available after the event.
  • Ardelyx currently markets two commercial products approved in the United States: IBSRELA® (tenapanor) & XPHOZAH® (tenapanor).
  • The company's pipeline includes Phase 3 development of IBSRELA for chronic idiopathic constipation (CIC) & RDX10531, a next-generation NHE3 inhibitor.
  • Ardelyx collaborates with partners to develop & commercialize its products outside the United States.
  • Investor inquiries can be directed to Lisa Caperelli, SVP, Investor Relations & Corporate Communications, while media inquiries should go to Lindsey Manuel, Associate Director, Corporate Communications.
Company
Ardelyx, Inc.
Keywords
Nasdaq:ARDX, Ardelyx, Inc.